CelerisAI · Program 2 · Scientific & Commercial Overview
Millions of heart patients are running out of options — not because the heart can't be helped, but because today's drugs hit a wall. CelerisAI is breaking through it.
The Problem
Think of your blood vessels like pipes carrying water. In a healthy heart, your body produces a natural molecule called Nitric Oxide (NO) — a built-in signal that tells your blood vessels to relax and widen, letting blood flow freely.
But in a failing heart, this Nitric Oxide supply dries up. And here's the critical problem: almost every drug used today relies on that Nitric Oxide signal to work. No signal, no effect.
It's like trying to boost a phone's Wi-Fi signal when the router itself is switched off. The problem isn't the phone — it's that the signal source is gone.
"Traditional therapeutics that rely on amplifying existing NO streams become physiologically useless as the disease progresses."
CelerisAI Clinical OverviewThe Solution
Instead of trying to amplify a Nitric Oxide signal that no longer exists, CelerisAI's molecule goes directly to the heart of the problem — activating two key biological switches without needing Nitric Oxide at all.
This pathway directly relaxes and widens blood vessels — reducing the strain on your heart without relying on any upstream signals.
This pathway supercharges the heart's pumping and filling ability — completely independently of the adrenaline system, avoiding the dangerous side effects of older drugs.
"By directly activating both pathways from within, the molecule operates at full efficacy even in low-NO, failing-heart environments — a first of its kind."
CelerisAI Mechanism OverviewHow We Compare
Every existing drug checks some boxes. None checks all of them. CelerisAI is designed to be the first.
| Drug / Therapy | Sustained Effect | NO-Independent | Dual Pathway | Safe Profile | Heart Failure |
|---|---|---|---|---|---|
| Nitrates (nitroglycerin) Loses effect in 24–48 hrs |
✗ | ✗ | ✗ | ✗ | ✗ |
| sGC Stimulators (vericiguat) Still needs some NO to work |
~ | ~ | ~ | ~ | ~ |
| PDE5 Inhibitors (sildenafil) Not approved for heart failure |
✗ | ✗ | ✗ | ✗ | ✗ |
| Hydralazine Reflex tachycardia risk |
~ | ~ | ~ | ~ | ~ |
| CelerisAI Dual Activator NO-independent · Dual pathway · Oral |
✓ | ✓ | ✓ | ✓ | ✓ |
The Opportunity
Three massive patient populations. Three conditions where current medicine is failing. One platform molecule designed to address all of them.
CelerisAI is building that answer — a novel molecule designed from first principles to work where everything else has stopped working.